Product
AMXT1501
2 clinical trials
22 indications
Indication
CancerIndication
Solid TumorIndication
Solid CarcinomaIndication
Advanced CancerIndication
Diffuse Intrinsic Pontine GliomaIndication
Ovarian CancerIndication
Breast CancerIndication
Papillary Thyroid CancerIndication
Head and Neck CancerIndication
Stomach CancerIndication
Mesothelioma, Malignant, PleuralIndication
Peritoneal MesotheliomaIndication
Esophageal cancerIndication
Diffuse Midline GliomaIndication
H3 K27M-MutantIndication
Endometrial CancerIndication
Cervical CancerIndication
MelanomaIndication
Colorectal CancerIndication
GliomaIndication
malignantIndication
NSCLCClinical trial
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-12-30
Clinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With CancerStatus: Recruiting, Estimated PCD: 2024-06-30